Exelixis, Inc. (LON:0IJO)

Market Cap	10.81B +46.2%
Revenue (ttm)	1.84B +9.2%
Net Income	648.65M +42.9%
EPS	2.40 +53.4%
Shares Out	n/a
PE Ratio	16.67
Forward PE	14.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188
Open	59.13
Previous Close	59.50
Day's Range	58.03 - 59.39
52-Week Range	33.81 - 59.70
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 1,077
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IJO

Financial Performance

In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error